Acta Med. 2018, 61: 79-85

https://doi.org/10.14712/18059694.2018.122

Endothelial Dysfunction in Children with Juvenile Psoriatic Arthritis

Lenka Turoňováa, Kristína Kubejováb, Karolína Vorčákovác, Peter Ďurdíka, Tatiana Péčovác, Klára Martináskovád

aDepartment of Pediatrics, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital Martin, Martin, Slovakia
bDepartment of Pediatrics and Adolescent Medicine, Pavol Jozef Šafárik University in Košice, Faculty of Medicine, Košice, Slovakia
cDepartment of Dermatology, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital Martin, Martin, Slovakia
dDepartment of Dermatology, A. Reiman’s Hospital, Prešov, Slovakia

Received February 27, 2018
Accepted August 7, 2018

References

1. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2015; 74(2): 326–32. <https://doi.org/10.1136/annrheumdis-2014-205675> <PubMed>
2. Ernste FC, Sánchez-Menéndez M, Wilton KM, Crowson CS, Matteson EL, Maradit Kremers H. Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based, cohort study. Arthritis Care Res 2015(7); 67: 1015–21. <https://doi.org/10.1002/acr.22536> <PubMed>
3. Polachek A, Touma Z, Anderson M, Eder L. Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies. Arthritis Care Res 2017; 69(1): 67–74. <https://doi.org/10.1002/acr.22926>
4. Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011(2); 270: 147–57. <https://doi.org/10.1111/j.1365-2796.2010.02310.x>
5. Kondratiouk S, Udaltsova N, Klatsky AL. Associations of psoriatic arthritis and cardiovascular conditions in a large population. Perm J 2008(4); 12: 4–8. <https://doi.org/10.7812/TPP/07-141>
6. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009; 68(7): 1131–5. <https://doi.org/10.1136/ard.2008.094839>
7. Han C, Robinson DW Jr., Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006; 33(11): 2167–72.
8. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2015; 74(2): 326–32. <https://doi.org/10.1136/annrheumdis-2014-205675> <PubMed>
9. Gulati AM, Semb AG, Rollefstad S, et al. On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trondelag Health Study. Ann Rheum Dis 2016; 75(5): 819–24. <https://doi.org/10.1136/annrheumdis-2014-206824>
10. Kibari A, Cohen A, Bitterman H, et al. Cardiac and cardiovascular morbidities in patients with psoriatic arthritis: a population-based cohort study. Ann Rheum Dis 2014; 73: 730–1. <https://doi.org/10.1136/annrheumdis-2014-eular.3830>
11. Li WQ, Han JL, Manson JE, et al. Psoriasis and risk of nonfatal cardiovascular disease in US women: a cohort study. Br J Dermatol 2012; 166(4): 811–8. <https://doi.org/10.1111/j.1365-2133.2011.10774.x> <PubMed>
12. Love TJ, Solomon DH, Karlson EW. The risk of myocardial infarction among patients with psoriatic arthritis. Arthritis Rheum 2010; 62 Suppl 10: 793.
13. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298(7): 321–8. <https://doi.org/10.1007/s00403-006-0703-z>
14. Bengtsson K, Forsblad-d’Elia H, Lie E, et al. Are ankylosing spondylitis, psoriatic arthritis and undifferntiated spondyloarthritis associated with an increased risk of cardiovascular disease? Arthritis Rheumatol 2015; 67 Suppl 10: 1057.
15. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19(3): 225–30. <https://doi.org/10.1023/B:EJEP.0000020447.59150.f9>
16. Galarraga B, Belch JJ, Pullar T, Ogston S, Khan F. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy. J Rheumatol 2010; 37(3): 521–8. <https://doi.org/10.3899/jrheum.090417>
17. Asha K, Sharma SB, Singal A, Aggarwal A. Association of carotid intima- media thickness with leptin and apoliprotein b/apoliprotein a-I ratio reveals imminent predictors of subclinical atherosclerosis in psoriasis patients. Acta Medica (Hradec Králové) 2014; 57(1): 21–7. <https://doi.org/10.14712/18059694.2014.4>
18. Kimhi O, Caspi D, Bornstein NM, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin arthritis Rheum 2007; 36(4): 203–9. <https://doi.org/10.1016/j.semarthrit.2006.09.001>
19. Brunner H, Cockcroft JR, Deanfield J, et al. Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. J Hypertens 2005; 23(2): 233–46. <https://doi.org/10.1097/00004872-200502000-00001>
20. Deanfield J, Donald A, Ferri C, et al. Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds. J Hypertens 2005; 23(1): 7–17. <https://doi.org/10.1097/00004872-200501000-00004>
21. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis. J Rheumatol 2004; 31(2): 390–2.
22. Giannini EG, Ruperto N, Ravelli A, Lovell DJ, Felson D, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheumatism 1997; 40(7): 1202–9. <https://doi.org/10.1002/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R>
23. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994; 37(12): 1761–9. <https://doi.org/10.1002/art.1780371209>
24. Corretti MC, Anderson TJ, Benjamin EJ, et al. International Brachial Artery Reactivity Task Force.Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39(2): 257–65. <https://doi.org/10.1016/S0735-1097(01)01746-6>
25. Stoll ML, Zurakowski D, Nigrovic LE, Nichols DP, Sundel RP, Nigrovic PA. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum 2006; 54(11): 3564–72. <https://doi.org/10.1002/art.22173>
26. Brezinski EA, Follansbee MR, Armstrong EJ, Armstrong AW. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis. Curr Pharm Des 2014; 20(4): 513–28. <https://doi.org/10.2174/138161282004140213123852>
27. Balci DD, Balci A, Karazincir S, et al. Increased carotid artery intima- media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol 2009; 23(1): 1–6. <https://doi.org/10.1111/j.1468-3083.2008.02936.x>
28. Ravelli A, Consolaro A, Schiappapietra B, Martini A. The conundrum of juvenile psoriatic arthritis. Clin Exp Rheumatol 2015; 33: 40–3.
29. Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol 2006; 1: 297–329. <https://doi.org/10.1146/annurev.pathol.1.110304.100100>
30. Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007; 190(1): 1–9. <https://doi.org/10.1016/j.atherosclerosis.2006.07.011>
31. Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74(3): 480–489. <https://doi.org/10.1136/annrheumdis-2014-206624> <PubMed>
32. Roubille C, Martel-Pelletier J, Davy JM, et al. Cardiovascularadverse effects of anti-inflammatory drugs. Antiinflamm Antiallergy Agents MedChem 2013; 12(1): 55–67. <https://doi.org/10.2174/1871523011312010008>
33. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al. Longterm exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology 2008; 47(1): 72–5. <https://doi.org/10.1093/rheumatology/kem311>
34. Avina-Zubieta JA, Abrahamowicz M, De Vera MA, et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population- based study. Rheumatology 2013; 52(1): 68–7. <https://doi.org/10.1093/rheumatology/kes353>
35. Nurmohamed M, Choy E, Lula S, et al. The impact of biologics and tofacitinib on cardiovascular risk factors and outcomes in patients with rheumatic disease. Drug Saf 2018; 41(5): 473–88. <https://doi.org/10.1007/s40264-017-0628-9> <PubMed>
36. Puig L, Strohal R, Husni ME, et al. Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate- to-severe psoriasis and psoriatic arthritis. J Dermatolog Treat 2015; 26(1): 7–15. <https://doi.org/10.3109/09546634.2013.860209>
37. Costa L, Caso F, Atteno M, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in CV risk in RA patients treated with biologics or tofacitinib a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 2014; 33(6): 833–9.
38. Van Dongen C, Agca R, Trivino L, Vogelzang E, Nurmohamed MT. Effect of etanercept therapy on lipid profile in patients with psoriatic arthritis. Ann Rheum Dis 2014; 73: 734–5. <https://doi.org/10.1136/annrheumdis-2014-eular.5166>
39. De Sanctis S, Marcovecchio ML, Gaspari S, et al. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis. J Rheumatol 2013; 40(6): 943–8. <https://doi.org/10.3899/jrheum.121281>
40. Gladman DD, Farewell VT, Wong K, et al. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998; 41(6): 1103–10. <https://doi.org/10.1002/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N>
41. Fenyo IM, Gafencu AV. The involvement of the monocytes/macrophages in chronic anflammation associated with atherosclerosis. Immunobiology 2013; 218(11): 1376–84. <https://doi.org/10.1016/j.imbio.2013.06.005>
42. Mestas J, Ley K. Monocyte-endothelial cell interaction in the development of atherosclerosis. Trends Cardiovasc Med 2008; 18(6): 228–32. <https://doi.org/10.1016/j.tcm.2008.11.004> <PubMed>
43. Fon Tacer K, Kuzman D, Seliskar M, et al. TNF – alpha interferes with lipid homeostasis and activates acute and proatherogenic processes. Physiol Genomics 2007; 31(2): 216–27.
44. Zhang H, Park Y, Chen X, et al. Role of anti TNF – alpha in vascular dysfunction. Clin Sci (Lond) 2009; 116: 219–30. <https://doi.org/10.1042/CS20080196> <PubMed>
45. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “highgrade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108(24): 2957–63. <https://doi.org/10.1161/01.CIR.0000099844.31524.05>
46. Hinks A, Martin P, Flynn E, et al. Investigation of type 1 diabetes and coeliac disease susceptibility loci for association with juvenile idiopathic arthritis. Ann Rheum Dis 2010; 69(12): 2169–72. <https://doi.org/10.1136/ard.2009.126938> <PubMed>
47. Vojtková J, Ciljaková M, Michnová Z, Turčan T. Chronic complications of diabetes mellitus related to the respiratory system. Pediatr Endocrinol Diabetes Metab 2012; 18(3): 112–5.
48. Edwards NM, Daniels SR, Claytor RP, et al. Physical activity is independently associated with multiple measures of arterial stiffness in adolescents and young adults. Metabolism 2012; 61(6): 869–72. <https://doi.org/10.1016/j.metabol.2011.10.016> <PubMed>
49. De Sanctis S, Marcovecchio ML, Gaspari S, et al. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis. J Rheumatol 2013; 40(6): 943–8. <https://doi.org/10.3899/jrheum.121281>
50. Prati C, Demougeot C, Guillot X, Godfrin-Valnet M, Wendling D. Endothelial dysfunction in joint disease. Joint Bone Spine 2014; 81(5): 386–91. <https://doi.org/10.1016/j.jbspin.2014.01.014>
51. Hjeltnes G, Hollan I, Forre O, et al. Endothelial function improves within 6 weeks of treatment with methotrexate or methotrexate in combinationwith a TNF-alpha inhibitor in rheumatoid arthritis patients. Scand J Rheumatol 2012; 41(3): 240–42. <https://doi.org/10.3109/03009742.2012.656698>
52. Van Eijk IC, Peters MJ, Serne EH, et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor-alpha blockade. Ann Rheum Dis 2009; 68(3): 362–66. <https://doi.org/10.1136/ard.2007.086777>
53. Syngle A, Vohra K, Sharma A, Kaur L. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade. Clin Rheumatol 2010; 29(7): 763–70. <https://doi.org/10.1007/s10067-010-1402-x>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive